This is a working overview of Synaptogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-11 and is reviewed periodically as new material appears.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
=== Elected officials === Mayor: Matthew Gentry Clerk-Treasurer: Tonya Thayer City Council, District 1: Mike Kincaid City Council, District 2: Keith Campbell City Council, District 3: Sandra Jasionowski City Council, District 4: Dick Robertson City Council, District 5: John Copeland City Council, At Large: Sierra Messenger City Council, At Large: Robert Hawkins
=== Fish === The skeleton, which forms the support structure inside the fish is either made of cartilage as in the Chondrichthyes, or bones as in the Osteichthyes. The main skeletal element is the vertebral column, composed of articulating vertebrae which are lightweight yet strong. The ribs attach to the spine and there are no limbs or limb girdles. They are supported only by the muscles. The main external features of the fish, the fins, are composed of either bony or soft spines called rays which, with the exception of the caudal fin (tail fin), have no direct connection with the spine. They are supported by the muscles which compose the main part of the trunk. Cartilaginous fish, such as sharks, rays, skates, and chimeras, have skeletons made entirely of cartilage. The lighter weight of cartilage allows these fish to expend less energy when swimming.
=== Offline lab analysis === When testing the quality of UPW, consideration is given to where that quality is required and where it is to be measured. The point of distribution or delivery (POD) is the point in the system immediately after the last treatment step and before the distribution loop. It is the standard location for the majority of analytical tests. The point of connection (POC) is another commonly used point for measuring quality of UPW. It is located at the outlet of the submain or lateral take off valve used for UPW supply to the tool. Grab sample UPW analyses are either complementary to the on-line testing or alternative, depending on the availability of the instruments and the level of the UPW quality specifications. Grab sample analysis is typically performed for the following parameters: metals, anions, ammonium, silica (both dissolved and total), particles by SEM (scanning electron microscope), TOC (total organic compounds) and specific organic compounds. Metal analyses are typically performed by ICP-MS (Inductively coupled plasma mass spectrometry). The detection level depends on the specific type of the instrument used and the method of the sample preparation and handling. Current state-of-the-art methods allow reaching sub-ppt (parts per trillion) level (< 1 ppt) typically tested by ICPMS. The anion analysis for seven most common inorganic anions (sulfate, chloride, fluoride, phosphate, nitrite, nitrate, and bromide) is performed by ion chromatography (IC), reaching single digit ppt detection limits.
Sources: en.wikipedia.org
The production of a RNA copy from a DNA strand is called transcription, and is performed by RNA polymerases, which add one ribonucleotide at a time to a growing RNA strand as per the complementarity law of the nucleotide bases. This RNA is complementary to the template 3′ → 5′ DNA strand, with the exception that thymines (T) are replaced with uracils (U) in the RNA and possible errors. In bacteria, transcription is carried out by a single type of RNA polymerase, which needs to bind a DNA sequence called a Pribnow box with the help of the sigma factor protein (σ factor) to start transcription. In eukaryotes, transcription is performed in the nucleus by three types of RNA polymerases, each of which needs a special DNA sequence called the promoter and a set of DNA-binding proteins—transcription factors—to initiate the process (see regulation of transcription below). RNA polymerase I is responsible for transcription of ribosomal RNA (rRNA) genes. RNA polymerase II (Pol II) transcribes all protein-coding genes but also some non-coding RNAs (e.g., snRNAs, snoRNAs or long non-coding RNAs). RNA polymerase III transcribes 5S rRNA, transfer RNA (tRNA) genes, and some small non-coding RNAs (e.g., 7SK). Transcription ends when the polymerase encounters a sequence called the terminator.
Haldane in 1929, suggested that life was preceded by the formation of what Haldane called a "hot dilute soup" of "colloidal organic substances", and which Oparin referred to as 'coacervates' (after de Jong) – particles composed of two or more colloids which might be protein, lipid or nucleic acid. These ideas strongly influenced the subsequent work of Sidney W. Fox on proteinoid microspheres.
6 August Weather Forecast about weather forecasting in the UK; Swedish Lennart Bengtsson of the European Centre for Medium-Range Weather Forecasts; Alistair Woodroffe and Brian Webster of the Met Office; numerical calculations began in the early 1950s with computers making 10,000 calculations a second but by the mid-1980s it was one billion; Meteosat-2 launched in June 1981; Steven Burke of the London Potato Futures Association; Capt Derek Ralph in a British Caledonian BAC One-Eleven flying to Aberdeen Airport; amateur weatherman Bill Foggitt; the weather centre and Lockheed C-5 Galaxy aircraft at RAF Mildenhall; conservationist Robin Page; narrated by Muriel Gray, directed by John Dollar, made by Uden Associates 13 August Made to Measure, essentially a re-edited, slightly updated edition of the August 1986 episodes on the F1 Ford turbocharged engine, with a few minutes of new content; in May 1987 Peter Collins watches the previous San Marino Grand Prix; Ford Cosworth V6 B187 cars: engine mapping; Dick Scammel, general head of engineering; Martin Walters, chief development engineer; the engine is dismantled, and damage is found; Geoff Goddard, chief racing engine designer; electromagnetic pulses from the engine affected the working of the engine computer circuitry; rogue signals were picked up by the engine computer, so causing erratic fuel injection; French F1 driver Patrick Tambay listens to the sound of the turbo; the turbo pressure would be limited to 2.5 in 1988, before turbos were banned for the 1989 season; the Italian Grand Prix circuit; each team is allowed two sets of qualifying tyres; the tyres on the rear axle warm up before the front axle; the Honda V6 engine could produce 1200 hp; chief designer Rory Byrne, and F1 aerodynamic forces. Narrated mostly by Martin Jarvis and partly by Eleanor Bron 20 August Twang, Bang, Kerang!, about the electric guitar; the Fat Tuesdays night club, and Les Paul; Glenn Wilson of the Institute of Psychiatry in London; Louis Jordan in the late 1940s; Charlie Christian developed the Gibson-ES150; Steve Howe of Yes; Burns London manufacturing guitars; Dave Russell; the body of the guitar was made of maple, a tonewood, and the fretboard of rosewood; the sound originates from the type of wood; Jerry Donohue of Fairport Convention; pickups made by Seymour Duncan; Chet Atkins; Andy Summers of The Police and Every Breath You Take; Francis Dunnery of It Bites, and Once Around the World. Narrated by John Hedges, produced by Patrick Uden, directed by Jeremy Llewellyn-Jones, made by Uden Associates 27 August What Goes Up..., about dismantling the AGR at Sellafield; it featured Tom Marsham CBE FRS (10 November 1923 – 12 October 1989) of UKAEA at Risley, Warrington (Birchwood Park), who was the reactor manager of Calder Hall in 1956. Narrated by Sue Jay, produced by Michael Blakstad, made by Workhouse Productions 3 September Hole in the Sky, about the depletion of the ozone layer, with Sir Bob Watson at NASA; the NERC's British Antarctic Survey had been measuring ozone levels since 1957 at the Halley Research Station, and a team led by Joe Farman noticed a hole in the layer; NASA had not noticed an ozone hole on its Nimbus 7 satellite, although the satellite had picked up all of the data, as Richard Stolarski of the Goddard Space Flight Center found; the ozone hole was caused by the polar vortex over the winter, where air movements outside of Antarctica are trapped, and there is not enough light to form new ozone; some people believed that the 1982 Mexican El Chichón volcanic eruption was to blame; in 1974 F. Sherwood Rowland and Mario Molina of the University of California, Irvine found that some chlorine compounds would destroy ozone by making chlorine monoxide, and both received the 1995 Nobel Prize in Chemistry for this discovery; the Chemical Manufacturers' Association (since 2000 the American Chemistry Council) and the National Science Foundation launched a new atmospheric survey at McMurdo Station, led by Susan Solomon of the Earth System Research Laboratories; Jerry D. Mahlman of the Geophysical Fluid Dynamics Laboratory at Princeton was attempting a computer model of the Antarctic atmosphere; Rafe Pomerance of the World Resources Institute; the greenhouse effect, described by James Hansen of the Goddard Institute for Space Studies, who claimed that the Earth's temperature would be 2 degrees higher by 2000, 3 degrees higher by 2010, and 4 to 7 degrees warmer by 2030; Richard E. Benedick. Directed by Linda Harrar, produced by Paula Apsell, made by WGBH, Uden Associates, Television Trust for the Environment and Sveriges Television. Originally a Nova documentary 24 September Dirty Money, about whether the environment can be cleaned up; the UK's first anti-pollution trade fair in March 1987, attended by William Waldegrave; Father Jim Conlon and Portglenone Abbey in N Ireland, with an anaerobic digester, which saved £1000 a month in gas cost, and the manure was sold for £25,000 a year; Mike Flux of ICI; biologist Paul Johnston of Greenpeace, in Teesside; the River Tees was the second-most polluted in the UK, with Douglas Ord of Northumbrian Water; Ken Murphy, and how Greenpeace attempted to block an effluent pipe near Immingham in March 1985; John Elkington, environmental writer; BioTechnica of Llanishen in Cardiff, reclaiming contaminated land on a former highly polluted gasworks site in Lancashire; Jutta Ditfurth; Hans-Georg Peine of BASF AG, and the Sandoz chemical spill in November 1986 in Switzerland; in 1983, ICI founded the first bioplastic company, called Marlborough Biopolymers, which made polyhydroxy butyrate; Dame Anita Roddick of The Body Shop, who worked with Friends of the Earth; Peter Baylis of the NERC Environmental Satellite Laboratory, which began in 1975, in the University of Dundee's Ewing Building, and largely provided the only UK archive of satellite environmental data. Narrated by Bob Peck, produced by Edward Poulter, directed by David Sharp, made by London Scientific Films 1 October Malltime. A US production, produced by Mike Wallington, made by George Haggerty, made by Kai Productions 8 October Anything You Can Do..., about new robotics; the five houses puzzle; Richard Gregory, professor of neuropsychology at the University of Bristol; Roger Mathias of Plessey Radar and the Multi-function Electronically Scanned Adaptive Radar (MESAR), began in 1982; Henry Thompson and speech recognition at the School of Informatics, University of Edinburgh; Robert Kowalski of the Department of Computing, Imperial College London; Margaret Boden of the University of Sussex; J. Michael Brady; Paul Caplin and robotics; Roy Bottomley of Meiko Scientific, and the transputer, developed in the UK; Plessey Laboratories at the Allen Clark Research Centre, and new chemical compounds for computer chip; logic programming and heuristics; the European Eureka Prometheus Project, an expert system. Narrated by Miriam Margolyes, produced by Michael Blakstad, directed by Catherine Robins, made by Workhouse Productions 22 October Command and Control, the chain of command of nuclear weapons; it featured the Air Force Research Laboratory. Directed by Clive Syddall, made by Twenty Twenty Vision 5 November Earthquake Country, about the San Andreas fault; Robert Wallace, chief scientist of the USGS; the 1906 earthquake caused the tectonic planes to move around seven metres; geologist Grove Karl Gilbert; an earthquake in the middle section of the fault was expected for around 1988; a 5.8 earthquake on 8 June 1934; geologist Kerry Sieh and paleoseismology; if an earthquake took place, coordination would be from the Joint Forces Training Base - Los Alamitos; earthquake engineer George W. Housner of Caltech; structural engineer Ray William Clough; earthquake engineer Luis Estava Maraboto of the Engineering Institute of the National Autonomous University of Mexico. Produced by Arabella Woods, directed by John Tchalenko, made by Red Rooster Films 12 November Nature's Technology, about the different types and the modelling of animal locomotion, and legged robots; robotic hands and bioengineer Stephen Jacobsen of the University of Utah; snake-arm robots; the 1986 Adaptive Suspension Vehicle (ASV) of Ohio State University, a hexapod robot, and Vincent Vohnout; active balance and Marc Raibert; the 1965 Walking Truck of General Electric; static stability and the Odex 1 six-legged robot; biomechanics and Robert McNeill Alexander, Professor of Zoology; WABOT-2 of Waseda University, optical music recognition and the NHK Symphony Orchestra of Japan conducted by Yuzo Toyama. Narrated by Adrienne Posta, directed by David Barlow, produced by Karl Sabbagh, made by InCA 19 November Britain Can Make It?, about making kitchen units in the UK and in Germany; the dual system of apprenticeship in Germany; Sig Prais of the National Institute of Economic and Social Research; the Britain Can Make It exhibition, where the fitted kitchen was first introduced in the UK; the Hungarian designer George Fejer was largely responsible for introducing fitted kitchens; Wolfgang Luckhaus of Poggenpohl of Germany, which also developed the fitted kitchen; in the 1960s the Germans introduced chipboard for kitchen manufacturing, which became industry-standard, with wipe-clean melamine resin facing (MFC); Hilary Steedman of the NIESR, and how the Germans built kitchens to order, whereas British companies simply built kitchens, whether ordered or not; Heal's of London introduced German kitchens to the UK in the early 1970s, in a hausfest; the German SieMatic kitchen company; Doug Gregory started The Symphony Group in 1970 after seeing chipboard, developing flatpack kitchen units, the Germans did not make flatpack kitchens, only assembled kitchens; David Love, buying director of MFI, which was helped by the flatpack revolution, but it was all largely an imitation of German products, and was a mostly standard product range; Symphony introduced computer production control in the 1980s, which the Germans had introduced in the early 1970s - this allowed much more variation of manufacturing to order, which was the main German method; employees of Symphony were largely unskilled, but German workers were largely skilled apprentices, who had passed exams in manufacturing; nearly all of German kitchens were built to order, so needed skilled workers; Walter Siekmann, production manager of Poggenpohl; German furniture manufacture was found in East Westphalia (Ostwestfalen); the Germans believed in more thorough technical training, and sold their products all over the world, but British companies had less-thorough training, and did not sell as worldwide as the Germans. Narrated by John Woodvine, directed by David Habakkuk, made by Riverside Television 26 November At the Edge, about the physical limits placed upon fighter pilots when flying high G capable modern aircraft, such as the F16 and the F18. Pilots are subjected to G-LOC in the Aerospace Medicine centrifuge in San Antonio, Texas. Narrated by Ray Brooks, written, produced and directed by Chris Haws, made by InCA
Sources: en.wikipedia.org
=== Characterization === Cox described Logan Roy as a "mysterious character in many ways. I have a lot of empathy for him. I think he's very misunderstood. I think he's a tragic figure", and compared him to Shakespeare's tragic kings, such as Henry IV. "Obviously there's Lear connotations, but it's also the father dealing with a child in his son Hal and not understanding him." David Rasche, who plays Karl Muller, suggested to Jesse Armstrong that his character became a confessor to Logan, "But I don't think Jesse wanted that. Jesse wanted Logan Roy, a man alone." Cox thinks of Logan as "quite Puritan [...] Logan's a bastard, but he's not an indecent bastard." On Logan's romantic relationships he has said "He clearly loves Marcia. There's this idea that he had this affair with Rhea, but I'm not sure that happened. Both Holly [Hunter] and I felt that hadn't actually happened, [...] The kids thinking they were having an affair was more them projecting", but also added that "he's not good at relationships at all. The female relationships in his life have been pretty disastrous". By the final season Cox noted that, Colin and Kerry, Logan's bodyguard and assistant respectively, were "the two people who matter to him most." Cox has expressed that he believes that Logan's greatest weakness was that "he loves his children desperately." In interviews with The New Yorker, Armstrong agreed with Cox that Logan loves his children, even if he had done "things which are antithetical to what most people would consider to be love."
== Other studies == Lung cancer - Life Length is working on developing an algorithm to detect patients at risk for lung cancer. With its telomere measurement platform, the test could potentially fill the gap in lung cancer screening techniques in a routine, minimally invasive, and low-cost way. Life Length was the European Seal of Excellence by the European Commission for its project proposal in lung cancer research. Childhood cancer - Life Length has conducted the largest childhood cancer research project to date, obtaining samples from about 100 children with cancer and healthy children. The aim of the study was to help oncology and hematology specialists make better decisions and increase the chances of these children beating cancer. Life Length has carried out these studies with the support of one of the most important children's hospitals in Spain, the Hospital Infantil Universitario Niño Jesús.
== G == Gabriel ethylenimine method Gabriel synthesis Gabriel–Colman rearrangement, Gabriel isoquinoline synthesis Gallagher–Hollander degradation Gassman indole synthesis Gastaldi synthesis Gattermann aldehyde synthesis Gattermann Koch reaction Gattermann reaction Geminal halide hydrolysis Gewald reaction Gibbs phthalic anhydride process Gilman reagent Glaser coupling Glycol cleavage Goldberg reaction Gomberg–Bachmann reaction Gomberg–Bachmann–Hey reaction Gomberg radical reaction Gould–Jacobs reaction Graebe–Ullmann synthesis Grignard degradation Griesbaum coozonolysis Grignard reaction Grob fragmentation Grubbs' catalyst in Olefin metathesis Grundmann aldehyde synthesis Gryszkiewicz–Trochimowski and McCombie method Guareschi–Thorpe condensation Guerbet reaction Gutknecht pyrazine synthesis
=== Pharmacokinetics === Little information thus far has been published on the clinical pharmacokinetics of phenibut. The drug is reported to be well-absorbed. It distributes widely throughout the body and across the blood–brain barrier. Approximately 0.1% of an administered dose of phenibut reportedly penetrates into the brain, with this said to occur to a much greater extent in young people and the elderly. Following a single 250 mg dose in healthy volunteers, its elimination half-life was approximately 5.3 hours and the drug was largely (63%) excreted in the urine unchanged. Some limited information has been described on the pharmacokinetics of phenibut in recreational users taking much higher doses (e.g., 1–3 grams) than typical clinical doses. In these individuals, the onset of action of phenibut has been reported to be 2 to 4 hours orally and 20 to 30 minutes rectally, the peak effects are described as occurring 4 to 6 hours following oral ingestion, and the total duration for the oral route has been reported to be 15 to 24 hours (or about 3 to 5 terminal half-lives).
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.